Monday, June 7, 2010

ACT Biotech's Telatinib receives orphan drug designation from FDA for treatment of gastric cancer

ACT Biotech's Telatinib receives orphan drug designation from FDA for treatment of gastric cancer..

Telatinib (see structure,  source : ChemBlink) :
(17-Demethoxy-17-allylaminogeldanamycin; Tanespimycin; 17-Allylaminogeldanamycin)


                  

Posted by https://www.med-chemist.com at 9:24 AM
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)